General form of registration statement for all companies including face-amount certificate companies

Intangible Asset (Details Narrative)

v3.10.0.1
Intangible Asset (Details Narrative) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 19, 2018
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Dec. 31, 2016
Capitalized cost   $ 3,037,147      
Business combination of tax basis   $ 1,782      
Number of shares acquired in exchange for common stock   2,090,301    
Proceeds from common stock       $ 4,270,000
Amortization expense   $ 25,435    
Weighted average amortization period for intangible asset   14 years      
Future amortization expense, twelve months   $ 788,495      
Future amortization expense, year two   788,495      
Future amortization expense, year three   788,495      
Future amortization expense, year four   788,495      
Future amortization expense, year five   788,495      
CoNCERT Pharmaceuticals, Inc [Member]          
Capitalized cost   11,038,929      
Transaction costs   $ 1,782      
Option exercised in exchange for common stock $ 8,000,000        
Number of shares acquired in exchange for common stock 2,090,301        
Percentage of common stock holdings 6.58%        
Percentage of issued and outstanding common stock diluted basis 5.93%        
Percentage of royalty 15.00%        
Proceeds from royalty receivable $ 8,000,000        
Proceeds from common stock 8,000,000        
CoNCERT Pharmaceuticals, Inc [Member] | Additional Paid-In Capital [Member]          
Proceeds from royalty receivable $ 8,000,000